Trial Profile
Role of Rapid Virologic Response in Determining Treatment Duration of Peginterferon Alfa-2b/Ribavirin in Chronic Hepatitis C Genotype 4.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 28 Feb 2008 The expected completion date for this trial is now 1 Apr 2007, as reported by clinicaltrials.gov.
- 25 Feb 2008 Status change from in progress to completed, as reported by clinicaltrials.gov.
- 21 Jul 2006 New trial record.